Abstract 10958: Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of Inflammatory Activity in Patients With Cardiac Sarcoidosis
Aims: The aim of this study was to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET).
Methods and Results: Twenty-five patients with CS (8 men, 17 women; mean age, 60 ± 9 years) diagnosed according to consensus criteria were enrolled in this study. We divided CS patients into two groups, known CS receiving corticosteroid therapy (Rx (+); n = 13) and new-onset CS (Rx (-); n = 12), and analyzed 3 distinct monocyte subsets (CD14+CD16–, CD14++CD16+, and CD14+–CD16+). Monocyte subsets were also analyzed in 7 Rx (-) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by 18F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14++CD16+ monocytes in Rx (+) patients (10.8 [0.2 to 23.5] %) was significantly lower than those in Rx (-) patients (25.2 [17.7 to 38.4] %, P = 0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14 to 0.46] to 0.14 [0.10 to 0.22] (P = 0.011). The proportion of CD 14++16+ monocytes showed a significant decrease from 25.8 [17.7 to 38.4] % to 9.7 [2.5 to 16.8] % (P = 0.002). The decrease in the proportion of CD 14++16+ monocytes was significantly correlated with the decrease in the COV of the SUV (r = 0.693, P = 0.006).
Conclusion: CD 14++16+ monocytes are a possible surrogate marker of inflammatory activity in CS.
Author Disclosures: M. Orii: None. T. Imanishi: None. M. Yokoyama: None. I. Teraguchi: None. T. Nishiguchi: None. Y. Shiono: None. K. Shimamura: None. T. Yamano: None. T. Tanimoto: None. Y. Matsuo: None. Y. Ino: None. T. Yamaguchi: None. T. Kubo: None. K. Hirata: None. A. Tanaka: None. T. Akasaka: None.
- © 2014 by American Heart Association, Inc.